Wechselwirkungen · Abseamed
Abseamed 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 2 000 IU/1 mL solution for injection in a pre-filled syringe Abseamed 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Abseamed 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Abseamed 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Abseamed 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Abseamed 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Abseamed 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Abseamed 10 000 IU/1 mL solution for injection in a pre-filled syringe Abseamed 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Abseamed 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.5 · PDF-Seite 15
HOS-117322 · Präparat HOS-094577
In female adult patients with metastatic breast cancer, subcutaneous co-administration of 40 000 IU/mL epoetin alfa with trastuzumab 6 mg/kg had no effect on the pharmacokinetics of trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trastuzumab (HOS-090897)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T17:02:00Z · SHA-256 3e1b737ee1405883d6ada05e33aebffc5aada961e1e56f0ea2f9f2b70e597f63 · Passage d84e75ada32f6a98168e61ace38ed8d038ba421d13afa6d955effd725aad0474 · Zeichen 752–946 im Abschnitt